Cargando…

Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial

BACKGROUND: Bleomycin–etoposid–cisplatin (BEP) chemotherapy is curative in most patients with disseminated germ cell cancer (GCC) but also associated with toxic actions and dysfunction in non-targeted tissues. We investigated changes in muscle function during BEP and the safety and efficacy of resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Christensen, J F, Jones, L W, Tolver, A, Jørgensen, L W, Andersen, J L, Adamsen, L, Højman, P, Nielsen, R H, Rørth, M, Daugaard, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090736/
https://www.ncbi.nlm.nih.gov/pubmed/24867693
http://dx.doi.org/10.1038/bjc.2014.273
_version_ 1782480690409897984
author Christensen, J F
Jones, L W
Tolver, A
Jørgensen, L W
Andersen, J L
Adamsen, L
Højman, P
Nielsen, R H
Rørth, M
Daugaard, G
author_facet Christensen, J F
Jones, L W
Tolver, A
Jørgensen, L W
Andersen, J L
Adamsen, L
Højman, P
Nielsen, R H
Rørth, M
Daugaard, G
author_sort Christensen, J F
collection PubMed
description BACKGROUND: Bleomycin–etoposid–cisplatin (BEP) chemotherapy is curative in most patients with disseminated germ cell cancer (GCC) but also associated with toxic actions and dysfunction in non-targeted tissues. We investigated changes in muscle function during BEP and the safety and efficacy of resistance training to modulate these changes. METHODS: Thirty GCC patients were randomly assigned to resistance training (resistance training group (INT), n=15) or usual care (CON, n=15) during 9 weeks of BEP therapy. Resistance training consisted of thrice weekly sessions of four exercises, 3–4 sets/exercise of 10–15 repetitions at 12–15 repetition maximum load. The primary endpoint was muscle fibre size, assessed in muscle biopsies from musculus vastus lateralis. Secondary endpoints were fibre phenotype composition, body composition, strength, blood biochemistry and patient-reported endpoints. Healthy age-matched subjects (REF, n=19) performed the same RT-programme for comparison purposes. RESULTS: Muscle fibre size decreased by −322 μm(2) (95% confidence interval (CI): −899 to 255; P=0.473) in the CON-group and increased by +206 μm(2) (95% CI: −384 to 796; P=0.257) in the INT-group (adjusted mean difference (AMD), +625 μm(2), 95% CI: −253 to 1503, P=0.149). Mean differences in type II fibre size (AMD, +823 μm(2), P=0.09) and lean mass (AMD, +1.49 kg, P=0.07) in favour of the INT-group approached significance. The REF-group improved all muscular endpoints and had significantly superior changes compared with the INT-group (P<0.05). CONCLUSIONS: BEP was associated with significant reduction in lean mass and strength and trends toward unfavourable changes in muscle fibre size and phenotype composition. Resistance training was safe and attenuated dysfunction in selected endpoints, but BEP blunted several positive adaptations observed in healthy controls. Thus, our study does not support the general application of resistance training in this setting but larger-scaled trials are required to confirm this finding.
format Online
Article
Text
id pubmed-4090736
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-40907362015-07-01 Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial Christensen, J F Jones, L W Tolver, A Jørgensen, L W Andersen, J L Adamsen, L Højman, P Nielsen, R H Rørth, M Daugaard, G Br J Cancer Clinical Study BACKGROUND: Bleomycin–etoposid–cisplatin (BEP) chemotherapy is curative in most patients with disseminated germ cell cancer (GCC) but also associated with toxic actions and dysfunction in non-targeted tissues. We investigated changes in muscle function during BEP and the safety and efficacy of resistance training to modulate these changes. METHODS: Thirty GCC patients were randomly assigned to resistance training (resistance training group (INT), n=15) or usual care (CON, n=15) during 9 weeks of BEP therapy. Resistance training consisted of thrice weekly sessions of four exercises, 3–4 sets/exercise of 10–15 repetitions at 12–15 repetition maximum load. The primary endpoint was muscle fibre size, assessed in muscle biopsies from musculus vastus lateralis. Secondary endpoints were fibre phenotype composition, body composition, strength, blood biochemistry and patient-reported endpoints. Healthy age-matched subjects (REF, n=19) performed the same RT-programme for comparison purposes. RESULTS: Muscle fibre size decreased by −322 μm(2) (95% confidence interval (CI): −899 to 255; P=0.473) in the CON-group and increased by +206 μm(2) (95% CI: −384 to 796; P=0.257) in the INT-group (adjusted mean difference (AMD), +625 μm(2), 95% CI: −253 to 1503, P=0.149). Mean differences in type II fibre size (AMD, +823 μm(2), P=0.09) and lean mass (AMD, +1.49 kg, P=0.07) in favour of the INT-group approached significance. The REF-group improved all muscular endpoints and had significantly superior changes compared with the INT-group (P<0.05). CONCLUSIONS: BEP was associated with significant reduction in lean mass and strength and trends toward unfavourable changes in muscle fibre size and phenotype composition. Resistance training was safe and attenuated dysfunction in selected endpoints, but BEP blunted several positive adaptations observed in healthy controls. Thus, our study does not support the general application of resistance training in this setting but larger-scaled trials are required to confirm this finding. Nature Publishing Group 2014-07-01 2014-05-27 /pmc/articles/PMC4090736/ /pubmed/24867693 http://dx.doi.org/10.1038/bjc.2014.273 Text en Copyright © 2014 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Clinical Study
Christensen, J F
Jones, L W
Tolver, A
Jørgensen, L W
Andersen, J L
Adamsen, L
Højman, P
Nielsen, R H
Rørth, M
Daugaard, G
Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial
title Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial
title_full Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial
title_fullStr Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial
title_full_unstemmed Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial
title_short Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial
title_sort safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090736/
https://www.ncbi.nlm.nih.gov/pubmed/24867693
http://dx.doi.org/10.1038/bjc.2014.273
work_keys_str_mv AT christensenjf safetyandefficacyofresistancetrainingingermcellcancerpatientsundergoingchemotherapyarandomizedcontrolledtrial
AT joneslw safetyandefficacyofresistancetrainingingermcellcancerpatientsundergoingchemotherapyarandomizedcontrolledtrial
AT tolvera safetyandefficacyofresistancetrainingingermcellcancerpatientsundergoingchemotherapyarandomizedcontrolledtrial
AT jørgensenlw safetyandefficacyofresistancetrainingingermcellcancerpatientsundergoingchemotherapyarandomizedcontrolledtrial
AT andersenjl safetyandefficacyofresistancetrainingingermcellcancerpatientsundergoingchemotherapyarandomizedcontrolledtrial
AT adamsenl safetyandefficacyofresistancetrainingingermcellcancerpatientsundergoingchemotherapyarandomizedcontrolledtrial
AT højmanp safetyandefficacyofresistancetrainingingermcellcancerpatientsundergoingchemotherapyarandomizedcontrolledtrial
AT nielsenrh safetyandefficacyofresistancetrainingingermcellcancerpatientsundergoingchemotherapyarandomizedcontrolledtrial
AT rørthm safetyandefficacyofresistancetrainingingermcellcancerpatientsundergoingchemotherapyarandomizedcontrolledtrial
AT daugaardg safetyandefficacyofresistancetrainingingermcellcancerpatientsundergoingchemotherapyarandomizedcontrolledtrial